ADVERTISEMENT
ADVERTISEMENT

Latest MODA™ Software Release from Lonza Enables Companies to Meet Updated Regulatory Guidance

MODA™ Version 3.3 delivers improved workflow with better analytics and reporting than ever before. Complete with a streamlined implementation and a risk-based validation solution, this software is the paperless solution for QC laboratories.

Lonza

Cologne (DE) / Walkersville, MD (USA), 25 October 2017 – Lonza’s MODA-EM™ Version 3.3 software enables microbiology Quality Control (QC) laboratories to comply with new regulatory guidelines. QC facilities have to manage the daily challenges of QC monitoring while meeting changing regulatory compliance mandates. Lonza's latest software release meets these evolving challenges with additional features focusing on data integrity, data visibility and data review.

 

MODA™ Version 3.3 delivers improved workflow with better analytics and reporting than ever before. Complete with a streamlined implementation and a risk-based validation solution, this software is the paperless solution for QC laboratories.

 

“It is essential for QC laboratories to be able to readily adapt to changing regulatory guidance. To aid this compliance MODA™ Version 3.3 features a new, fully searchable audit trail that lets scientists easily track changes made through a sample’s lifecycle,” said Sinéad Cowman, EU Business Development Manager for Lonza Informatics....

 

The new software has been designed to meet end user requirements and features enhanced scheduling and calendar capabilities for simplified sample management. It also offers web-based dashboards so that metrics and results can be accessed from anywhere with an internet connection. Scientists in QC laboratories are also supported with a validation documentation package that meets current industry standards and regulatory requirements, with execution and pre-validated service options available. 

 

More information on MODA™ Version 3.3 and other QC testing solutions is available on www.lonza.com/moda

 

About Lonza 

Following the closing of the Capsugel acquisition, Lonza further strengthened its position as one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life.

 

An integrated solutions provider serving the healthcare continuum, Lonza offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries. In addition to drinking water sanitizers, nutraceuticals, antidandruff agents and other personal care ingredients, the company provides agricultural products, advanced coatings and composites and microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

 

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 50 major manufacturing and R&D facilities and nearly 14,000 full-time employees worldwide. Further information can be found at www.lonza.com.

 

Lonza Contact Information

Lonza Cologne GmbH

Manager Marketing Communications

Petra Haberkamm

Tel +49 221 991990

petra.haberkamm@lonza.com

 

Lonza Group Ltd

Head External Communications

Constance Ward 

Tel +41 61 316 8840

constance.ward@lonza.com

 

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

 

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
ADVERTISEMENT